TherapeuticsMD Q3 revenue $20.9M, net loss $29.0M; cash drops to $27.1M

TherapeuticsMD, Inc.

2022-Q3 EPS reported $3.73 revenue$68,811,000

Net revenue $20.9M, down 18% YoY; net loss $29.0M ($3.13/sh) vs $47.4M loss YoY.
Operating expenses cut $22.2M YoY to $37.9M; product gross margin 82% vs 78%.
ANNOVERA revenue $10.4M (-$1.4M YoY), Rx up 10% YoY; IMVEXXY $6.9M; BIJUVA $2.7M.
Cash $27.1M at Sep 30, down from $65.1M at Dec 31; post-quarter $7M investment from Rubric Capital.
Net debt and preferred stock liability $117.1M; no earnings call due to strategic alternatives review.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TherapeuticsMD, Inc. reported the third quarter ended September 30, 2022 results: revenue $20.9 million, net income $29.0 million, EPS $3.13 per basic and diluted share.

Period: the third quarter ended September 30, 2022
Revenue: $20.9 million
Net income: $29.0 million
EPS: $3.13 per basic and diluted share
Result: reported results

Exact text from the filing

Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-037633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.